Risk Group-adapted Adjuvant Radiotherapy for WHO Grade I and II Skull Base Meningioma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2019 Apr 7

PMID 30953136

Citations 8

Authors

Sangjoon Park

Yoon Jin Cha

Sang Hyun Suh

Ik Jae Lee

Kyu-Sung Lee

Chang-Ki Hong

Jun Won Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: Salvage treatment including surgery and radiotherapy (RT) for recurrent or progressive meningioma is not an easy task, especially for the skull base location. And yet, criteria for adjuvant radiotherapy after initial surgery are not clearly defined for WHO grade I/II meningioma. We determined prognostic factors for recurrence and evaluated the benefit of risk group-adapted adjuvant RT for WHO grade I/II meningioma in the skull base.

Methods: We reviewed 272 patients who underwent surgery and were pathologically confirmed with WHO grade I or II skull base meningioma between January 2000 and July 2017. Subgroup analyses were performed for WHO grade I (259 patients) and WHO grade II (13 patients) meningiomas to evaluate the benefit of RT in each subgroup.

Results: Patients with WHO grade II meningiomas tended to present more neurologic symptoms and to receive RT more frequently. In prognostic factor analysis, tumor size (p = 0.039), surgical extent (p < 0.001), and RT (p = 0.005) were associated with recurrence-free survival (RFS). In subgroup analysis of WHO grade I, RFS was significantly better in RT group after matching other variables. The risk stratification was performed using three risk factors (petroclival location, tumor size, Simpson grade) in WHO grade I patients, and significantly different RFS was observed according to the risk group in non-RT patients.

Conclusions: Tumor size, Simpson grade, and adjuvant RT were prognostic factors. The risk group-adapted approach can facilitate the selection of patients who may benefit from adjuvant RT for WHO grade I/II skull base meningiomas.

Citing Articles

Comparison of adjuvant radiation versus observation and salvage radiation after subtotal resection of a WHO grade I skull base meningioma: a propensity score-adjusted analysis.

Kosanam A, Ma J, White A, Murayi R, Soni P, Recinos P J Neurooncol. 2025; .

PMID: 39998721 DOI: 10.1007/s11060-025-04980-8.

Interdisciplinary Therapeutic Approaches to Atypical and Malignant Meningiomas.

Trakolis L, Petridis A Cancers (Basel). 2023; 15(17).

PMID: 37686527 PMC: 10486693. DOI: 10.3390/cancers15174251.

Inflammatory Tumor Microenvironment in Cranial Meningiomas: Clinical Implications and Intraindividual Reproducibility.

Wach J, Lampmann T, Guresir A, Vatter H, Herrlinger U, Becker A Diagnostics (Basel). 2022; 12(4).

PMID: 35453901 PMC: 9029024. DOI: 10.3390/diagnostics12040853.

Proliferative Potential, and Inflammatory Tumor Microenvironment in Meningioma Correlate with Neurological Function at Presentation and Anatomical Location-From Convexity to Skull Base and Spine.

Wach J, Lampmann T, Guresir A, Vatter H, Herrlinger U, Becker A Cancers (Basel). 2022; 14(4).

PMID: 35205781 PMC: 8870248. DOI: 10.3390/cancers14041033.

FORGE: A Novel Scoring System to Predict the MIB-1 Labeling Index in Intracranial Meningiomas.

Wach J, Lampmann T, Guresir A, Schuss P, Vatter H, Herrlinger U Cancers (Basel). 2021; 13(14).

PMID: 34298854 PMC: 8306435. DOI: 10.3390/cancers13143643.

References

Perry A, Scheithauer B, Stafford S, Lohse C, Wollan P . "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer. 1999; 85(9):2046-56. DOI: 10.1002/(sici)1097-0142(19990501)85:9<2046::aid-cncr23>3.0.co;2-m. View

Ayerbe J, Lobato R, de la Cruz J, Alday R, Rivas J, Gomez P . Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien). 1999; 141(9):921-32. DOI: 10.1007/s007010050398. View

Hug E, DeVries A, Thornton A, Munzenride J, Pardo F, Hedley-Whyte E . Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol. 2000; 48(2):151-60. DOI: 10.1023/a:1006434124794. View

Van Havenbergh T, Carvalho G, Tatagiba M, Plets C, Samii M . Natural history of petroclival meningiomas. Neurosurgery. 2002; 52(1):55-62; discussion 62-4. DOI: 10.1097/00006123-200301000-00006. View

Pirzkall A, Debus J, Haering P, Rhein B, Grosser K, Hoss A . Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. Int J Radiat Oncol Biol Phys. 2003; 55(2):362-72. DOI: 10.1016/s0360-3016(02)03809-9. View

Chang J, Chang J, Choi J, Park Y, Chung S . Complications after gamma knife radiosurgery for benign meningiomas. J Neurol Neurosurg Psychiatry. 2003; 74(2):226-30. PMC: 1738258. DOI: 10.1136/jnnp.74.2.226. View

Simpson D . The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957; 20(1):22-39. PMC: 497230. DOI: 10.1136/jnnp.20.1.22. View

Huffmann B, Reinacher P, Gilsbach J . Gamma knife surgery for atypical meningiomas. J Neurosurg. 2005; 102 Suppl:283-6. DOI: 10.3171/jns.2005.102.s_supplement.0283. View

Milker-Zabel S, Zabel A, Schulz-Ertner D, Schlegel W, Wannenmacher M, Debus J . Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys. 2005; 61(3):809-16. DOI: 10.1016/j.ijrobp.2004.07.669. View

10.

Kreil W, Luggin J, Fuchs I, Weigl V, Eustacchio S, Papaefthymiou G . Long term experience of gamma knife radiosurgery for benign skull base meningiomas. J Neurol Neurosurg Psychiatry. 2005; 76(10):1425-30. PMC: 1739368. DOI: 10.1136/jnnp.2004.049213. View

11.

Park C, Jung H, Kim J, Paek S, Kim D . The selection of the optimal therapeutic strategy for petroclival meningiomas. Surg Neurol. 2006; 66(2):160-5. DOI: 10.1016/j.surneu.2005.12.024. View

12.

Milker-Zabel S, Zabel-du Bois A, Huber P, Schlegel W, Debus J . Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys. 2007; 68(3):858-63. DOI: 10.1016/j.ijrobp.2006.12.073. View

13.

Yang S, Park C, Park S, Kim D, Chung Y, Jung H . Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2007; 79(5):574-80. DOI: 10.1136/jnnp.2007.121582. View

14.

Hamm K, Henzel M, Gross M, Surber G, Kleinert G, Engenhart-Cabillic R . Radiosurgery/stereotactic radiotherapy in the therapeutical concept for skull base meningiomas. Zentralbl Neurochir. 2008; 69(1):14-21. DOI: 10.1055/s-2007-992138. View

15.

Gorman L, Ruben J, Myers R, Dally M . Role of hypofractionated stereotactic radiotherapy in treatment of skull base meningiomas. J Clin Neurosci. 2008; 15(8):856-62. DOI: 10.1016/j.jocn.2007.05.020. View

16.

Iwai Y, Yamanaka K, Ikeda H . Gamma Knife radiosurgery for skull base meningioma: long-term results of low-dose treatment. J Neurosurg. 2008; 109(5):804-10. DOI: 10.3171/JNS/2008/109/11/0804. View

17.

Aghi M, Carter B, Cosgrove G, Ojemann R, Amin-Hanjani S, Martuza R . Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery. 2009; 64(1):56-60. DOI: 10.1227/01.NEU.0000330399.55586.63. View

18.

Rosenberg L, Prayson R, Lee J, Reddy C, Chao S, Barnett G . Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys. 2009; 74(2):427-32. DOI: 10.1016/j.ijrobp.2008.08.018. View

19.

Sughrue M, Rutkowski M, Aranda D, Barani I, McDermott M, Parsa A . Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010; 113(5):1036-42. DOI: 10.3171/2010.3.JNS091966. View

20.

Kane A, Sughrue M, Rutkowski M, Shangari G, Fang S, McDermott M . Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer. 2011; 117(6):1272-8. PMC: 3795515. DOI: 10.1002/cncr.25591. View